These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 14566218
1. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression? Castrogiovanni P, Blardi P, De Lalla A, Dell'Erba A, Auteri A. Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218 [Abstract] [Full Text] [Related]
3. Fluoxetine once every third day in the treatment of major depressive disorder. Tural U, Onder E. Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120 [Abstract] [Full Text] [Related]
5. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T. Biol Psychiatry; 2006 Jun 01; 59(11):1052-60. PubMed ID: 16581036 [Abstract] [Full Text] [Related]
6. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Nemeroff CB, Thase ME, EPIC 014 Study Group. J Psychiatr Res; 2007 Jun 01; 41(3-4):351-9. PubMed ID: 16165158 [Abstract] [Full Text] [Related]
7. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Hsiao CC. Psychoneuroendocrinology; 2006 Aug 01; 31(7):839-46. PubMed ID: 16716529 [Abstract] [Full Text] [Related]
8. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M. Ann Clin Psychiatry; 2007 Aug 01; 19(1):5-8. PubMed ID: 17453655 [Abstract] [Full Text] [Related]
9. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. Int Clin Psychopharmacol; 2008 Sep 01; 23(5):269-75. PubMed ID: 18703936 [Abstract] [Full Text] [Related]
13. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M. Psychiatry Res; 2008 Oct 30; 161(1):116-20. PubMed ID: 18755514 [Abstract] [Full Text] [Related]
16. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, Fava M. Psychosomatics; 2002 Oct 30; 43(4):310-6. PubMed ID: 12189257 [Abstract] [Full Text] [Related]
17. Plasma catecholamine levels after fluoxetine treatment in depressive patients. Blardi P, de Lalla A, Auteri A, Iapichino S, Dell'Erba A, Castrogiovanni P. Neuropsychobiology; 2005 Oct 30; 51(2):72-6. PubMed ID: 15741747 [Abstract] [Full Text] [Related]